SOUTH SAN FRANCISCO, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in several upcoming

SOUTH SAN FRANCISCO, Calif. , May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will host a virtual investor event that will showcase competitive

Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,

Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive

SOUTH SAN FRANCISCO, Calif. , April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report first quarter 2021 financial results on Thursday,

Collaboration Agreement to Market AZOVA COVID-19 Test Collection Kit Online AZOVA Digital Health Platform Provides Patient Questionnaire, Process for Prescription, Kit Purchase , Sample Collection, and Secure Delivery of Test Results SOUTH SAN FRANCISCO, Calif.

Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to $138.1 million Collaboration with PLT Tech to Market CyTOF Technology to Clinical Labs in China SOUTH

PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a

SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that George Mason University in Fairfax, Va.

Researchers Seek Insight into Development and Progression of Multisystem Inflammatory Syndrome in Children Study Exemplifies Increasing Use of CyTOF Technology in Clinical Research SOUTH SAN FRANCISCO, Calif. , Feb. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative